Medicare Enrolled
Dr. Katrina Fischer
Hematology & Oncology · San Mateo, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Mixed engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Fischer from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Fischer?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Fischer
Dr. Katrina Fischer is a hematology & oncology specialist in San Mateo, CA, with 11 years of NPI registration. Based on federal Medicare data, Dr. Fischer performed 173,053 Medicare services across 3,768 unique beneficiaries.
Between the years covered by Open Payments, Dr. Fischer received a total of $1,958 from 12 pharmaceutical and/or device companies across 30 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Payments are distributed across multiple categories and often reflect legitimate professional engagement with the medical industry. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Fischer is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 11 years in practice
▲ Top 3% volume in CA
$1,958 industry payments
Medicare Practice Summary
Medicare Utilization ↗173,053
Medicare services
Top 3% in CA for hematology & oncology
3,768
Unique beneficiaries
$12
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~15,732 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Injectafer) An intravenous injection of ferric carboxymaltose, an iron replacement medication. |
30,750 | $1 | $3 |
| Iron infusion (Feraheme) An injection of ferumoxytol used to treat iron deficiency anemia in patients not on dialysis. |
30,090 | $0 | $2 |
| Darbepoetin injection (Aranesp) for anemia An injection of darbepoetin alfa used for non-end-stage renal disease purposes. |
25,500 | $2 | $8 |
| Daratumumab injection (Darzalex) An injection containing daratumumab and hyaluronidase-fihj administered under the skin. |
14,400 | $38 | $121 |
| Denosumab injection (Prolia/Xgeva) | 12,840 | $18 | $59 |
| Pembrolizumab injection (Keytruda) | 12,800 | $43 | $138 |
| Oxaliplatin chemotherapy injection This procedure involves the administration of oxaliplatin, a chemotherapy medication, via injection. The dosage specified is 0.5 mg. |
10,900 | $0 | $1 |
| Epoetin alfa injection (Retacrit) for anemia An injection of a biosimilar form of epoetin alfa used for non-end-stage renal disease purposes. The dose administered is 1000 units. |
7,141 | $6 | $21 |
| Paclitaxel chemotherapy injection | 5,686 | $0 | $1 |
| Anti-nausea injection (fosaprepitant) An injection of fosaprepitant, a medication used to prevent nausea and vomiting. |
4,800 | $0 | $1 |
| Omalizumab injection (Xolair) for asthma/allergy | 4,350 | $30 | $96 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
2,025 | $0 | $1 |
| Blood draw (venipuncture) Insertion of a needle into a vein to collect a blood sample. |
1,557 | $8 | $33 |
| Infliximab infusion (Remicade) An injection of infliximab, excluding biosimilar versions, administered in a 10 mg dose. |
1,430 | $26 | $85 |
| Complete blood count (CBC) with differential An automated laboratory test that measures the levels of red blood cells, white blood cells, and platelets in the blood, including a breakdown of the different types of white blood cells. |
1,403 | $8 | $33 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
966 | $106 | $347 |
| Anti-nausea injection (Aloxi/palonosetron) | 770 | $1 | $3 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
696 | $12 | $39 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
497 | $148 | $485 |
| Additional sequential IV infusion, 1 hour or less This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less. |
449 | $26 | $82 |
| Pegfilgrastim-jmdb injection An injection of pegfilgrastim-jmdb, a biosimilar medication. The dose specified is 0.5 mg. |
432 | $104 | $337 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
393 | $75 | $246 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
369 | $118 | $376 |
| Fluorouracil injection, 500 mg Administration of a 500 mg dose of fluorouracil medication via injection. |
332 | $2 | $7 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
246 | $57 | $184 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 219 | $3 | $9 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
171 | $25 | $80 |
| Zoledronic acid injection, 1 mg An injection of zoledronic acid administered at a dose of 1 mg. |
161 | $6 | $21 |
| Carboplatin chemotherapy injection, 50 mg Administration of a 50 mg dose of carboplatin, a chemotherapy medication, via injection. |
149 | $2 | $7 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
148 | $1 | $3 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
125 | $65 | $209 |
| Comprehensive metabolic blood panel A blood test that measures a group of chemicals, including glucose, electrolytes, and kidney and liver function markers. |
115 | $10 | $26 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
98 | $14 | $44 |
| Office visit for established patient An office visit for an existing patient that may not require the healthcare professional to be present. |
93 | $20 | $66 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
89 | $140 | $448 |
| Chronic care management, first 30 minutes This service covers the initial 30 minutes of care coordination for patients with two or more chronic conditions. It is provided personally by a healthcare professional each calendar month. |
86 | $68 | $227 |
| Additional hour of intravenous infusion This code represents each additional hour of intravenous infusion beyond the initial hour for therapy, prevention, or diagnosis. |
79 | $18 | $58 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
71 | $11 | $43 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
70 | $59 | $185 |
| Unclassified drug A medication that does not fit into standard HCPCS or CPT classification categories. |
66 | $0 | $41 |
| Vitamin B-12 injection An injection of vitamin B-12 (cyanocobalamin) with a dose of up to 1000 mcg. |
65 | $1 | $5 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
57 | $67 | $205 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
46 | $2 | $7 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
43 | $30 | $96 |
| New patient office visit, complex (60-74 min) | 43 | $176 | $592 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 42 | $137 | $439 |
| Venipuncture for blood collection A procedure to draw blood from a vein for medical testing or analysis. |
31 | $81 | $282 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
29 | $101 | $305 |
| Intravenous hydration infusion, 31-60 minutes Administration of fluids into a vein to maintain hydration. This procedure involves an infusion lasting between 31 and 60 minutes. |
24 | $30 | $93 |
| Intravenous push injection of new drug or substance A healthcare provider injects a new medication or substance directly into a vein using a push technique. |
24 | $48 | $157 |
| Telephone medical discussion, 11-20 minutes A phone conversation with a physician lasting between 11 and 20 minutes. |
22 | $77 | $246 |
| Ferritin level test (iron stores) A blood test that measures the level of ferritin, a protein that stores iron in the body. |
20 | $13 | $29 |
| Concurrent intravenous infusion Administration of medication or fluid into a vein for therapy, prevention, or diagnosis while another infusion is being given. |
18 | $18 | $56 |
| New patient office visit (30-44 min) An initial office visit for a new patient lasting between 30 and 44 minutes. This code is used when the total time spent on the date of the encounter falls within this range. |
15 | $88 | $303 |
| Lactate dehydrogenase (LDH) level test A blood test that measures the amount of lactate dehydrogenase, an enzyme found in many body tissues. It helps assess tissue damage or disease. |
12 | $6 | $22 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
36.7% high complexity
60.0% medium
3.2% routine
Industry Payment Transparency
Open Payments through 2024 ↗$1,958
Total received (2018-2024)
Avg $326/year across 6 years
Bottom 44% in CA for hematology & oncology
12
Companies
30
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Other
Charitable contributions, space rental, and other categories
$1,315 (67.2%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$610 (31.2%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$32 (1.6%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$1,066
2023
$442
2022
$72
2021
$157
2019
$120
2018
$100
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Novartis Pharmaceuticals Corporation
$1,016
GlaxoSmithKline, LLC.
$33
Tempus AI, Inc
$16
Top 3 companies account for 100.0% of 2024 payments
All-time payments by company (2018-2024) ›
Novartis Pharmaceuticals Corporation
$1,016
NOVARTIS PHARMACEUTICALS CORPORATION
$299
GlaxoSmithKline, LLC.
$182
Genentech USA, Inc.
$120
Eisai Inc.
$100
E.R. Squibb & Sons, L.L.C.
$98
PFIZER INC.
$32
Incyte Corporation
$27
CTI BioPharma Corp.
$27
Myriad Genetic Laboratories, Inc.
$21
Novocure Inc.
$18
Tempus AI, Inc
$16
Top 3 companies account for 76.5% of all-time payments
Associated products mentioned in payments ›
Alecensa · IBRANCE · JAKAFI · KISQALI · Lenvima · NUCALA · OPDIVO · OPTUNE LUA (NOVOTTF-200T) · Vonjo · ZEJULA · myRisk
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Payments are distributed across multiple categories with no single dominant type.
Geographic Context
Hematology & oncology specialists within 10 mi
152
Per 100K population
20.4
County median income
$156,000
Nearest hospital
SAN MATEO MEDICAL CENTER
2.7 mi
2.7 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Fischer is a mixed practice specialist, with above-average Medicare volume (top 3% in CA), with mixed engagement industry engagement.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Fischer experienced with iron infusion (injectafer)?
Based on Medicare claims data, Dr. Fischer performed 30,750 iron infusion (injectafer) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Fischer receive payments from pharmaceutical companies?
Yes. Dr. Fischer received a total of $1,958 from 12 companies across 30 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Fischer's costs compare to other hematology & oncology specialists in San Mateo?
Dr. Fischer's average Medicare payment per service is $12. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Fischer) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in San Mateo
Browse hematology & oncology specialists in San Mateo ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in CA
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in CA
Which CA hematology & oncology specialists receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
NOVARTIS PHARMACEUTICALS CORPORATION Payments to Doctors
See all physicians who received payments from NOVARTIS PHARMACEUTICALS CORPORATION.
By company
GlaxoSmithKline, LLC. Payments to Doctors
See all physicians who received payments from GlaxoSmithKline, LLC.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology